Table 1 ∣.
Patient demographics and disease characteristics at enrollment
| All | Cohort | |||||
|---|---|---|---|---|---|---|
| A | B | |||||
| N | % | N | % | N | % | |
| Sex | ||||||
| Female | 46 | 80.7 | 6 | 66.7 | 40 | 83.3 |
| Male | 11 | 19.3 | 3 | 33.3 | 8 | 16.7 |
| ECOG performance status | ||||||
| 0 | 25 | 43.9 | 5 | 55.6 | 20 | 41.7 |
| 1 | 28 | 49.1 | 4 | 44.4 | 24 | 50.0 |
| 2 | 4 | 7.0 | 0 | 0 | 4 | 8.3 |
| Median age, years (range) | 53 (28–80) | 53 (34–75) | 52 (28–80) | |||
| Initial primary tumor diagnosis | ||||||
| Breast | 35 | 61.4 | 4 | 44.4 | 31 | 64.6 |
| HR+ HER2+ | 9 | – | – | – | 9 | – |
| HR+ HER2− | 7 | – | – | – | 7 | – |
| HR+ HER2 unknown | 1 | – | – | – | 1 | – |
| HR− HER2+ | 7 | – | – | – | 7 | – |
| Triple-negative | 11 | – | 4 | – | 7 | – |
| Melanoma | 2 | 3.5 | – | – | 2 | 4.2 |
| BRAF mutation | 1 | – | – | – | 1 | – |
| NSCLC-not otherwise specified | 7 | 12.3 | 1 | 11.1 | 6 | 12.5 |
| EGFR mutation | 2 | – | – | – | 2 | – |
| ALK rearrangement | 1 | – | – | – | 1 | – |
| Ovarian | 1 | 1.8 | 1 | 11.1 | – | – |
| Renal cell carcinoma | 1 | 1.8 | – | – | 1 | 2.1 |
| Extraosseous osteosarcoma | 1 | 1.8 | – | – | 1 | 2.1 |
| Esophageal | 1 | 1.8 | – | – | 1 | 2.1 |
| Neuroendocrine carcinoma | 1 | 1.8 | 1 | 11.1 | – | – |
| Pituitary | 2 | 3.5 | – | – | 2 | 4.2 |
| Carcinoma | 1 | 1.8 | – | – | 1 | 1.8 |
| Neuroendocrine tumor | 1 | 1.8 | – | – | 1 | 1.8 |
| Prostate | 1 | 1.8 | – | – | 1 | 2.1 |
| Small-cell lung cancer | 2 | 3.5 | 1 | 11.1 | 1 | 2.1 |
| Unknown primary | 1 | 1.8 | 1 | 11.1 | – | – |
| Advanced sinonasal ACC | 1 | 1.8 | – | – | 1 | 2.1 |
| Alveolar soft-part sarcoma | 1 | 1.8 | – | – | 1 | 2.1 |
| Extracranial metastatic disease? | 40 | 70.2 | 8 | 88.9 | 32 | 66.7 |
| Lung | 28 | – | 4 | – | 24 | – |
| Lymph node | 22 | – | 8 | – | 14 | – |
| Bone | 14 | – | 0 | – | 14 | – |
| Liver | 9 | – | 3 | – | 6 | – |
| Visceral | 7 | – | 2 | – | 5 | – |
| Adrenal | 3 | – | 0 | – | 3 | – |
| More than 1 BM? | ||||||
| No | 11 | 19.3 | 4 | 44.4 | 7 | 14.6 |
| Yes | 46 | 80.7 | 5 | 55.6 | 41 | 83.4 |
| Months since diagnosis of primary tumor, median (range) | 36 (1–295) | 23 (3–69) | 38 (1–295) | |||
| Prior systemic therapies | 50 | 87.7 | 8 | 88.9 | 42 | 87.5 |
| Median number of systemic therapies (range) | 3 (1–16) | 4 (1–6) | 3 (1–16) | |||
| Prior BM-directed treatment | ||||||
| Intracranial radiation | 41 | 71.9 | 0 | 0 | 41 | 85.4 |
| Median number of prior rounds of radiation (range) | 1 (1–6) | |||||
| Prior brain surgery | 45 | 78.9 | 1a | 11.1 | 44 | 91.7 |
| Median number of prior surgeries (range) | 2 (1–4) | |||||
| Prior systemic therapy | 25 | 43.9 | 0 | 0 | 25 | 52.1 |
| Median number of systemic therapies (range) | 2 (1–15) | |||||
| Chemotherapy | 21 | 36.8 | 0 | 0 | 20 | 41.7 |
| Targeted therapy | 16 | 28.1 | 0 | 0 | 16 | 33.3 |
| Antibody–drug conjugate | 9 | 15.8 | 0 | 0 | 9 | 18.8 |
a
The one patient in cohort A who received prior brain surgery underwent a ventriculoperitoneal shunt and a craniotomy (for diagnostic purposes) and immediately afterwards, the patient enrolled onto the study for intracranial disease given multiple new untreated BMs. ACC, adenoid cystic carcinoma.